Levilimab
Based on 1 Customer Validation
Levilimab (BCD-089) is an IL-6 receptor blocker that binds to both membrane-bound and soluble IL-6Rα. Levilimab inhibits IL-6 signaling, including classical signaling and trans-signaling, by blocking IL-6 binding. Levilimab can be used in research on rheumatoid arthritis and COVID-19.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 97.52%
- CAS No.: 2035008-70-7
- 분자량:145.7 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
|
IL-6 |
In Vitro
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized IL-6R alpha Protein, Human (CHO, HY-P7223) can bind Levilimab. The EC50 for this effect is 24.18 ng/mL.
Chemical Information
-
CAS No. 2035008-70-7
-
Appearance Liquid
-
분자량 145.7 kDa
-
Color Colorless to light yellow
-
SMILES
[Levilimab]
-
Synonyms
BCD-089
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)